MapLight director granted RSUs and options
MapLight Therapeutics director Babler Martin received new equity awards as part of non-employee director compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MapLight Therapeutics director Babler Martin received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units and a stock option for 29,804 shares of Voting Common Stock at an exercise price of $28.64 per share.
The RSUs and option were granted under the 2025 Equity Incentive Plan and will vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service. Following these grants, Martin holds 7,864 shares of Voting Common Stock directly and the newly granted option covering 29,804 underlying shares.
Insider Trade Summary
Grant/Award: 37,668 shares
Grant/Award
2 txns
Insider
Babler Martin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 29,804 | $0.00 | $0.00 |
| Grant/Award | Voting Common Stock | 7,864 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 29,804 contracts (Direct);
Voting Common Stock — 7,864 shares (Direct)
Footnotes (3)
- F1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
- F2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
- F3. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
Key Figures
RSUs granted: 7,864 units
Stock options granted: 29,804 options
Option exercise price: $28.64 per share
+3 more
6 metrics
RSUs granted
7,864 units
Restricted stock units granted June 23, 2026
Stock options granted
29,804 options
Stock option covering Voting Common Stock
Option exercise price
$28.64 per share
Conversion/exercise price for stock option
Shares underlying option
29,804 shares
Underlying Voting Common Stock for option
Shares held after RSU grant
7,864 shares
Total Voting Common Stock after transaction
Option expiration
June 22, 2036
Expiration date of stock option grant
Key Terms
restricted stock units, 2025 Equity Incentive Plan, Continuous Service, non-employee director compensation policy, +1 more
5 terms
restricted stock units financial
"Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2025 Equity Incentive Plan financial
"granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan")"
Continuous Service financial
"subject to the Continuous Service (as defined in the Plan) of the Reporting Person"
non-employee director compensation policy financial
"This grant was made pursuant to the Issuer's non-employee director compensation policy."
Stock Option (right to buy) financial
"Represents a stock option granted pursuant to the Plan."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MapLight Therapeutics (MPLT) director Babler Martin receive in this Form 4?
Babler Martin received equity-based compensation consisting of 7,864 restricted stock units and a stock option for 29,804 shares. Both awards were granted under MapLight Therapeutics’ 2025 Equity Incentive Plan as part of its non-employee director compensation policy.
How do the RSUs granted to Babler Martin by MapLight Therapeutics (MPLT) vest?
The 7,864 restricted stock units vest in three equal annual installments starting June 23, 2027. Vesting is conditioned on Babler Martin’s Continuous Service with MapLight Therapeutics on each applicable vesting date, as defined in the company’s 2025 Equity Incentive Plan.
What are the key terms of Babler Martin’s new stock option at MapLight Therapeutics (MPLT)?
The stock option covers 29,804 shares of Voting Common Stock at an exercise price of $28.64 per share. It vests in three equal annual installments beginning June 23, 2027, subject to Babler Martin’s Continuous Service with MapLight Therapeutics on each vesting date.
Are Babler Martin’s new equity awards at MapLight Therapeutics (MPLT) open-market purchases or compensation grants?
These transactions are compensation grants, not open-market purchases. The Form 4 identifies them with transaction code “A” as awards under the 2025 Equity Incentive Plan and the company’s non-employee director compensation policy, with no cash price paid at grant.
When will Babler Martin’s RSUs and options from MapLight Therapeutics (MPLT) fully vest?
Both the 7,864 RSUs and the 29,804-share stock option vest in three equal annual tranches starting June 23, 2027. Full vesting occurs after three years, assuming Babler Martin continues to satisfy the Continuous Service requirement on each annual vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
